Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/26/2024 | $1.50 → $7.50 | Buy → Hold | Jefferies |
11/17/2023 | $5.00 → $1.00 | Buy → Neutral | UBS |
11/10/2023 | $3.00 → $2.00 | Overweight → Neutral | Piper Sandler |
3/17/2023 | $7.00 → $4.00 | Outperform → Market Perform | TD Cowen |
9/7/2022 | $7.50 | Hold | Truist |
1/7/2022 | $14.00 | Buy | UBS |
10/20/2021 | $15.00 | Buy | Jefferies |
9/13/2021 | $14.00 | Neutral → Overweight | Piper Sandler |
ClareMedica Health Partners to become "Stalking Horse" Bidder to Acquire CareMax's Core Centers' Assets CareMax, Inc. (NASDAQ:CMAX, CMAXW)) ("CareMax" or the "Company"), a leading technology-enabled value-based care delivery system, today announced that it has entered into a "stalking horse" purchase agreement with ClareMedica Health Partners ("ClareMedica"), a leader in value-based primary care serving patients in Florida, pursuant to which ClareMedica will acquire CareMax's core centers' assets including a vast majority of CareMax's operating clinics (the "Core Centers' Assets"). The transaction will be implemented pursuant to a previously announced prearranged chapter 11 plan support
Revere Medical Enters into Agreement to Acquire CareMax's Management Services Organization Agreement in Principle Reached with "Stalking Horse" for Core Centers' Assets Sale Transactions to be Implemented Through an Expedited Prearranged Chapter 11 Plan Supported by 100% of CareMax's Secured Lenders CareMax Secures $30.5 Million in Debtor in Possession Financing to Support Operations and Continuing Provision of Healthcare Services Throughout Restructuring Process CareMax, Inc. (NASDAQ:CMAX, CMAXW)) ("CareMax" or the "Company"), a leading technology-enabled value-based care delivery system, today announced it has entered into an agreement to sell its management services organization
Second Quarter Medicare Advantage Membership of 104,000, up 1% year-over-year Second Quarter Total Revenue of $198.6 million, down 12% year-over-year CareMax, Inc. (NASDAQ:CMAX, CMAXW))) ("CareMax" or the "Company"), a leading technology-enabled value-based care delivery system, today announced financial results for the second quarter ended June 30, 2024. "Although our medical expense ratio continued to run higher than target levels, we were able to manage toward another quarter of sequential improvement in MER in the second quarter, and we continued to make progress against our clinical initiatives," said Carlos de Solo, Chief Executive Officer. Mr. de Solo continued, "Additiona
Jefferies downgraded CareMax from Buy to Hold and set a new price target of $7.50 from $1.50 previously
UBS downgraded CareMax from Buy to Neutral and set a new price target of $1.00 from $5.00 previously
Piper Sandler downgraded CareMax from Overweight to Neutral and set a new price target of $2.00 from $3.00 previously
8-K - CareMax, Inc. (0001813914) (Filer)
8-K - CareMax, Inc. (0001813914) (Filer)
NT 10-Q - CareMax, Inc. (0001813914) (Filer)
SC 13G/A - CareMax, Inc. (0001813914) (Subject)
SC 13G - CareMax, Inc. (0001813914) (Subject)
SC 13D/A - CareMax, Inc. (0001813914) (Subject)
Met 2023 Guidance for Medicare Advantage Membership and Total Revenue Year-end 2023 Medicare Advantage Membership of 111,500, up 19% year-over-year Full Year 2023 Total Revenue of $751.1 million, up 19% year-over-year Exploring Strategic Options to Maximize Value of Certain Assets and Generate Further Liquidity CareMax, Inc. (NASDAQ:CMAX, CMAXW))) ("CareMax" or the "Company"), a leading technology-enabled value-based care delivery system, today announced financial results for the fourth quarter and full year ended December 31, 2023. "In the fourth quarter, we began taking major steps with the goal of solidifying the long-term viability of our business," said Carlos de Solo, C
Third Quarter Medicare Advantage Membership of 107,000, up 171% year-over-year Third Quarter Total Revenue of $201.8 million, up 28% year-over-year Reaffirming Full Year 2023 Revenue Guidance; Updating Full Year 2023 Medicare Advantage Membership and Adjusted EBITDA Guidance CareMax, Inc. (NASDAQ:CMAX, CMAXW))) ("CareMax" or the "Company"), a leading technology-enabled value-based care delivery system, today announced financial results for the third quarter ended September 30, 2023. "Tomorrow marks one year since the acquisition of our national MSO and nearly two and a half years of rapid growth in our patient and provider base. Over that period, we experienced fluctuations in o
CareMax, Inc. ("CareMax") (NASDAQ:CMAX, CMAXW))), a leading value-based care delivery system, announced today that it will release its financial results for the third quarter 2023 before the opening of the financial markets on Thursday, November 9, 2023, and host a conference call at 8:30 am Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (888) 330-2508 for U.S. participants, or (240) 789-2735 for international participants, and referencing conference ID 7874605. A live audio webcast and replay of the event will also be available on the "Events & Presentations" section of CareMax's investor relations website at ir.caremax.com. About CareM
3 - CareMax, Inc. (0001813914) (Issuer)
3 - CareMax, Inc. (0001813914) (Issuer)
4 - CareMax, Inc. (0001813914) (Issuer)